S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:NITE - Nightstar Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$25.41
MA: $25.41
$25.41
52-Week Range N/A
Volume40 shs
Average Volume185,808 shs
Market Capitalization$852.25 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NITE
CUSIPN/A
Phone44-20-7062-2777

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.89 per share

Profitability

Net Income$-36,860,000.00

Miscellaneous

Employees47
Market Cap$852.25 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NITE News and Ratings via Email

Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions

What is Nightstar Therapeutics' stock symbol?

Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."

How were Nightstar Therapeutics' earnings last quarter?

Nightstar Therapeutics PLC (NASDAQ:NITE) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.13. View Nightstar Therapeutics' Earnings History.

What price target have analysts set for NITE?

9 equities research analysts have issued 12-month price objectives for Nightstar Therapeutics' stock. Their forecasts range from $25.18 to $26.00. On average, they expect Nightstar Therapeutics' stock price to reach $25.53 in the next twelve months. View Analyst Price Targets for Nightstar Therapeutics.

What is the consensus analysts' recommendation for Nightstar Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nightstar Therapeutics.

What are Wall Street analysts saying about Nightstar Therapeutics stock?

Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (5/7/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $42/share price target on Nightstar Therapeutics. This morning, Spark (N) announced a definitive agreement to be acquired by Roche (RHHBY, NC) for $4.8 billion, or $114.50/share (a 122% premium). While we believe the primary driver of the acquisition was Spark’s hemophilia A program, we have observed a trend in late- stage gene therapy company acquisitions. Given that Nightstar is one of the furthest along with a Phase 3 trial reading out next year, we believe the company deserves a seat at the table for acquisition talks and interest from pharma." (2/26/2019)

Has Nightstar Therapeutics been receiving favorable news coverage?

News articles about NITE stock have been trending extremely negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nightstar Therapeutics earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Nightstar Therapeutics.

Who are some of Nightstar Therapeutics' key competitors?

What other stocks do shareholders of Nightstar Therapeutics own?

Who are Nightstar Therapeutics' key executives?

Nightstar Therapeutics' management team includes the folowing people:
  • Mr. David Fellows, CEO & Director (Age 62)
  • Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)
  • Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)
  • Brian Luque, Sr. Mang. of Investor Relations
  • Mr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40)

When did Nightstar Therapeutics IPO?

(NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

How big of a company is Nightstar Therapeutics?

Nightstar Therapeutics has a market capitalization of $0.00. The company earns $-36,860,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Nightstar Therapeutics employs 47 workers across the globe.View Additional Information About Nightstar Therapeutics.

What is Nightstar Therapeutics' official website?

The official website for Nightstar Therapeutics is http://www.nightstartx.com/.

How can I contact Nightstar Therapeutics?

Nightstar Therapeutics' mailing address is 10 MIDFORD PLACE 2ND FLOOR, LONDON X0, W1T5BJ. The company can be reached via phone at 44-20-7062-2777 or via email at [email protected]


MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  402
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel